{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Scottsdale&page=20&state=Arizona", "query": { "state": "Arizona", "city": "Scottsdale", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 3691, "total_pages": 370, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Scottsdale&page=21&state=Arizona&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Scottsdale&page=19&state=Arizona&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T21:36:25.319Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002622", "title": "Talc in Treating Patients With Malignant Pleural Effusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "Talc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 501, "start_date": "1994-12", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2016-06-28", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 224, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002622" }, { "nct_id": "NCT04622007", "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tomivosertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2021-06-02", "completion_date": "2024-12-09", "has_results": false, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 131, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04622007" }, { "nct_id": "NCT02267707", "title": "Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms", "Cholestasis" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-05-27", "completion_date": "2016-02-10", "has_results": false, "last_update_posted_date": "2019-11-01", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Detroit, Michigan", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02267707" }, { "nct_id": "NCT01272037", "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Ductal Carcinoma In Situ", "Invasive Breast Carcinoma", "Multicentric Breast Carcinoma", "Multifocal Breast Carcinoma", "Synchronous Bilateral Breast Carcinoma" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Systemic Chemotherapy", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5018, "start_date": "2011-02-28", "completion_date": "2027-01-08", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 1435, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272037" }, { "nct_id": "NCT01516892", "title": "A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine Disorders" ], "interventions": [ { "name": "onabotulinumtoxinA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 716, "start_date": "2011-12", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01516892" }, { "nct_id": "NCT04046445", "title": "Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "MSS", "Stage IV Colon Cancer", "Stage IV Rectal Cancer", "Metastatic Colorectal Cancer", "Liver Metastasis Colon Cancer" ], "interventions": [ { "name": "ATP128", "type": "DRUG" }, { "name": "BI 754091", "type": "DRUG" }, { "name": "VSV-GP128", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amal Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2019-07-22", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046445" }, { "nct_id": "NCT03199586", "title": "Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Pancreas Cancer", "Prostate Cancer", "Lung Cancer", "Colon Cancer", "Esophagus Cancer", "Liver Cancer", "Ovary Cancer", "Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies" ], "interventions": [ { "name": "NP-G2-044", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novita Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-12-21", "completion_date": "2020-05-07", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Duarte, California • New York, New York", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03199586" }, { "nct_id": "NCT02071173", "title": "Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiac Resynchronization Therapy" ], "interventions": [ { "name": "ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2244, "start_date": "2014-04-14", "completion_date": "2020-10-06", "has_results": true, "last_update_posted_date": "2021-01-07", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 96, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 85 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071173" }, { "nct_id": "NCT03580369", "title": "A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Ligelizumab", "type": "BIOLOGICAL" }, { "name": "Omalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1072, "start_date": "2018-10-17", "completion_date": "2022-06-14", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03580369" }, { "nct_id": "NCT05914805", "title": "A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alopecia, Androgenetic" ], "interventions": [ { "name": "Clascoterone 5% solution", "type": "DRUG" }, { "name": "Vehicle solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cassiopea SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 762, "start_date": "2023-08-17", "completion_date": "2025-07-16", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-31T21:36:25.319Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Troy", "state": "Michigan" }, { "city": "Warren", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05914805" } ] }